Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis

BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), sodium-glucose cotransporter-2 (SGLT2) inhibitors were demonstrated to lower cardiovascular mortality (CV death) and hospitalization for heart failure (HHF); however, the advantages of SGLT2 inhibitors in heart failure with mildly...

Descripción completa

Detalles Bibliográficos
Autores principales: Treewaree, Sukrit, Kulthamrongsri, Narathorn, Owattanapanich, Weerapat, Krittayaphong, Rungroj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941559/
https://www.ncbi.nlm.nih.gov/pubmed/36824458
http://dx.doi.org/10.3389/fcvm.2023.1046194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941559/
https://www.ncbi.nlm.nih.gov/pubmed/36824458
http://dx.doi.org/10.3389/fcvm.2023.1046194

Ejemplares similares